CSIMarket
 
Corvus Pharmaceuticals Inc   (CRVS)
Other Ticker:  
 
 
Price: $1.9000 $0.02 1.064%
Day's High: $1.99 Week Perf: -5.47 %
Day's Low: $ 1.88 30 Day Perf: -14.8 %
Volume (M): 173 52 Wk High: $ 4.19
Volume (M$): $ 329 52 Wk Avg: $1.89
Open: $1.88 52 Wk Low: $0.61



 Market Capitalization (Millions $) 93
 Shares Outstanding (Millions) 49
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative immuno-oncology therapies. The company is known for its expertise in the field of immunotherapy and aims to transform the treatment of cancer by harnessing the body's immune system to fight the disease.

Corvus Pharmaceuticals has a diverse pipeline of drug candidates, with a particular focus on targeting the adenosine-cancer axis. Adenosine is a molecule that suppresses the immune response and is commonly found in the tumor microenvironment. By targeting this pathway, the company intends to enhance the immune system's ability to effectively eliminate cancer cells.

The company's lead drug candidate, CPI-006, is an antagonist antibody that is being developed for various cancer indications. CPI-006 has shown promising results in preclinical and early clinical studies, and Corvus Pharmaceuticals is currently advancing it through various clinical trials.

Overall, Corvus Pharmaceuticals Inc is dedicated to the development of novel immuno-oncology therapies that can improve the lives of patients with cancer. Through its innovative approach, the company aims to address unmet medical needs and improve treatment outcomes in oncology.


   Company Address: 863 Mitten Road, Suite 102 Burlingame 94010 CA
   Company Phone Number: 900-4520   Stock Exchange / Ticker: NASDAQ CRVS
   CRVS is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Licensing Agreement

Soquelitinib Granted Orphan Drug Designation for the Treatment of T Cell Lymphoma, Initiating Phase 3 Clinical Trials

Published Thu, Feb 8 2024 9:05 PM UTC

In recent years, the field of oncology has witnessed significant advancements in the development of targeted therapies. As part of this trend, Corvus Pharmaceuticals, a renowned biopharmaceutical company, has received orphan drug designation for its novel drug candidate, Soquelitinib, intended for the treatment of Peripheral T Cell Lymphoma (PTCL).Orphan Drug Designation:On ...

Product Service News

Soquelitinib: A Ray of Hope in the Fight against Peripheral T Cell Lymphoma (PTCL)

Published Sat, Dec 9 2023 5:00 PM UTC



In a recent press release, Corvus Pharmaceuticals has presented new interim data from its Phase 1/1b clinical trial for soquelitinib (formerly known as CPI-818). The data reveals encouraging anti-tumor activity and durable responses, providing substantial support for advancing soquelitinib into a Phase 3 registrational clinical trial. This breakthrough in therapy o...

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc Defies Odds with $6.913 Million Operating Deficit Improvement, Setting a Positive Trend in Q3 2023 Results

Corvus Pharmaceuticals Inc Faces Operating Deficit but Shows Signs of Improvement in Third Quarter 2023 Results
Investors in the pharmaceutical industry have been keeping a close eye on Corvus Pharmaceuticals Inc as they analyze the company's third quarter 2023 results. The company reported an operating deficit of $-5.56 million for the period, but there were positive indicators compared to the previous year.
During the same quarter in 2022, Corvus Pharmaceuticals Inc had an operating deficit of $-12.473 million, meaning they have managed to improve their financial situation this year. This improvement suggests a positive trend for the company and is an important indicator for investors to consider.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc Shines Bright with Reduced Losses and Promising Growth in Q2 2023 Financial Results

Corvus Pharmaceuticals Inc, a growing biopharmaceutical company, recently reported their financial results for the second quarter of 2023. Investors had a mixed reaction to the company's performance, as there were no significant changes in revenue compared to the previous quarter. However, they did take note of the company's improved operating loss, indicating that Corvus Pharmaceuticals is becoming more economically efficient.
During the period from April to June 2023, Corvus Pharmaceuticals recorded an operating loss of $-5.622 million. This marked an improvement from the previous year's second quarter, where the company reported an operating loss of $-7.013 million. It is evident that the company has made strides in reducing their losses as they continue to grow their revenue streams.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc's First Quarter 2023 Effort Sees Negative ROE and Net Loss of $41 Million

Corvus Pharmaceuticals Inc's recent financial report showed a cumulative net loss of $-41 million during the 12 months ending in the first quarter of 2023. This resulted in a negative return on equity (ROE) of -65.4%. Compared to the fourth quarter of 2021, the company's total ranking in terms of ROE deteriorated from 0 to 1617.
While 71 other companies within the Major Pharmaceutical Preparations industry had a higher return on equity, investors were not expecting any major improvements during the January to March 31, 2023 earnings season at CRVS.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com